GlassScriptPhysician profile
Christi Ann Rogers
NPI 1073091914
$6,731.11
in general payments reported to CMS, 2019-2025
26 companies · $710 in 2025
The $710 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,873 · 2022: $1,570 · 2023: $1,291 · 2024: $1,287 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.30 | 2021-2025 | |
| Novo Nordisk INC | $878.63 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $743.68 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $640.34 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $549.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $546.00 | 2021-2024 | Trintellix |
| Amgen INC. | $423.77 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.01 | 2021-2025 | Jardiance |
| Pfizer INC. | $295.30 | 2023-2025 | |
| Radius Health, INC. | $189.17 | 2021-2024 | Tymlos |
| Merz North America, INC. | $160.82 | 2023-2025 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $141.41 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $129.94 | 2021 | |
| Exact Sciences Corporation | $108.49 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $93.69 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.31 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $47.80 | 2021 | |
| Acella Pharmaceuticals, LLC | $34.52 | 2024-2025 | NP Thyroid 60 |
| Corcept Therapeutics | $32.92 | 2023 | Korlym |
| Abbott Laboratories | $22.92 | 2022 | |
| Biogen, INC. | $19.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.59 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2023 | |
| Amarin Pharma, INC. | $13.79 | 2021 | |
| Currax Pharmaceuticals LLC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christi Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.